TD Waterhouse Canada’s Xenon Pharmaceuticals XENE Stock Holding History

TD Waterhouse Canada’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.85K	Hold	130	–	–	﹤0.01%	1887
2026 Q1	$7.33K	Buy	+130	New	+$5.99K	﹤0.01%	1829

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

TD Waterhouse Canada's XENE Position: Q2 2026 in Review

TD Waterhouse Canada held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 130 shares worth $7.85K. The position accounts for ﹤0.01% of the portfolio, ranked #1887.

TD Waterhouse Canada first reported a position in XENE in Q1 2026 and has held it in 2 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

TD Waterhouse Canada held 130 shares of Xenon Pharmaceuticals worth $7.85K as of Q2 2026.
TD Waterhouse Canada left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #1887 holding.
TD Waterhouse Canada first reported a position in Xenon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.